King's Research Portal

DOI:

[10.12968/bjon.2018.27.22.1321](https://doi.org/10.12968/bjon.2018.27.22.1321)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Cardillo, L., Cahill, F., Wylie, H., Williams, A., Zylstra, J. L., Davies, A. R., Fullwood, L., & Van Hemelrijck, M. (2018). Patients' perspectives on opt-out consent for observational research: systematic review and focus group. *British Journal of Nursing*, 27(22), 1321-1329. <https://doi.org/10.12968/bjon.2018.27.22.1321>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 **ABSTRACT**

2 **Background** Observational research is increasingly important in clinical decision-making. Opt-out
3 consent has been proposed as a more practical way to obtain participants' consent for such. We
4 evaluated patients' views on opt-out consent for observational research by identifying perceived
5 benefits and barriers.

6 **Methods** Following a systematic literature review of research on participants' perspectives on opt-
7 out consent, we conducted a focus group interview with oncological patients and their family
8 members.

9 **Results** We identified thirteen articles detailing perspectives on opt-out consent. Perceived
10 advantages included benefitting medicine and future generations. These findings were confirmed
11 in our focus group. The main reported barriers to opt-out consent are concerns regarding privacy
12 and the sharing of data with third parties. Participants also demonstrated concerns on insufficient
13 education on opt-out consent.

14 **Conclusions** Participants demonstrated willingness to participate in observational studies utilizing
15 opt-out consent. Special focus should be placed on outlining existing safeguards in research.

16

17 **Key points**

- 18 • Our results include a comprehensive systematic review of the literature following the
- 19 PRISMA guidelines.
- 20 • Additional qualitative data was obtained from a focus group, an experienced research
- 21 consumer panel, and an existing real world evidence database.
- 22 • Participants demonstrated willingness to participate in studies utilizing opt-out consent,
- 23 however this was impeded by some key concerns.
- 24 • Special focus should be placed on outlining the existing safeguards in research.
- 25 • Improving public opinion on studies using presupposed consent could lead to decreased
- 26 selection bias.
- 27 • Nonetheless, the scope for opt-out consent has been further limited by the provisions of
- 28 the General Data Protection Regulation (GDPR) which came into force in May 2018.
- 29

30 **Reflective questions**

- 31 • How do patients perceive an opt-out consent procedure?
- 32 • What are current barriers for patients to approve of opt-out consent?
- 33 • How does the interpretation of the General Data Protection Regulation affect the use of
- 34 opt-out consent in academic research?
- 35

36 INTRODUCTION

37 The significance of providing personalized care to patients is increasingly recognised in
38 current medical practice. An invaluable tool to this purpose is *real-world evidence* (RWE). RWE
39 refers to data, mostly observational, collected in contexts other than typical research settings,
40 such as during routine clinical care.(1, 2) Unlike other forms of data collection, including
41 randomised controlled trials, RWE has greater external validity and better applicability to
42 underrepresented patient groups due to decreased selection bias.(1, 3-5) Hence, the use of RWE is
43 permissive to clinicians more equitably addressing the needs of singular patients in real-world,
44 day-to-day contexts.

45 Yet maintaining the benefits of RWE can be challenging, as much validity can be lost whilst
46 obtaining **participants'** consent. Selection bias is bound to occur when **participant** consent is
47 secured via the currently widespread opt-in recruitment strategy, as has been demonstrated in
48 various studies.(6-9) It can be argued, however, that when the collection of observational RWE
49 poses remote risks of harm to the **participants** involved, opt-out consent can be utilised.(10-12)

50 **Opt-out systems rely on implicit consent, where willingness to participate is tacit or**
51 **presumed and can be retracted by active objection.(13)** **These** generate more complete data, with
52 less biased samples and improved response rates, as compared to opt-in consent strategies.(9, 14,
53 15) Moreover, opt-out consent is preferable in **large cohorts**, where other strategies could be too
54 costly or impractical to enact.(12, 16-18) However, it is unclear whether public opinion
55 unequivocally supports opt-out. Existing studies demonstrate **the public holds** varying views about
56 which process of consent is ideal.

57 Hence, the aim of this study was to explore cancer patients' opinions of opt-out consent
58 for the secondary use of their health records. Following a systematic review of the literature, we
59 conducted a focus group with oncological patients and their relatives, furtherly exploring their

60 opinions and concerns. In addition, we assessed the experience of opt-out consent in real-time
61 clinical practice in our institution.

62

63 **METHODS**

64 **Systematic literature review**

65 This systematic review was conducted following the PRISMA statement for completing
66 systematic reviews and meta-analyses (19). A computerised literature search of the Ovid
67 MEDLINE database to identify full text and abstracts published between 1946 and November 21st
68 2017 was performed. The following search strategy was used: Opt-out and (consent or view* or
69 perspective* or ethic* or attitude*) and (research or biobank or trial or health record* or medical
70 record*). All references of the selected articles were checked, including hand searches.

71 The final articles were chosen based on the following set of inclusion criteria: the publication
72 pertained to a patient-focused study which clearly defined opt-out; the manuscript was published
73 in English. The literature review and data collection was conducted by LC and reviewed by MVH.

74 Initially, titles were reviewed to assess whether they met inclusion criteria. Titles that
75 indicated the study met these criteria progressed to an abstract review. Upon inclusion after this
76 step, the full manuscript was thoroughly checked to evaluate inclusion and exclusion criteria.
77 Figure 1 provides more detailed information regarding the exclusion process. The following details
78 were recorded for each study: author, year of publication, country where study was undertaken,
79 number of participants, and method of data collection.

80

81 **Focus group participants and setting**

82 Patients being treated at Guy's Cancer Centre (London, UK) for urological tumours, breast
83 or lung tumours were recruited to participate in a focus group by invitational flyers handed out

whilst visiting the Centre for routine appointments. Family members and relatives were also encouraged to participate. We aimed to have at least 10 participants as to ensure all relevant themes and opinions would be picked up (20). Participants were introduced to the purpose of the focus group and asked to complete an anonymous demographic questionnaire. Informed consent was obtained for the recording and processing of the interview. The focus group was conducted by a research nurse and two note-taking assistants. Initially, broad questions about participants' previous exposure to research were discussed. Subsequently, a brief presentation on selection bias and opt-out research with secondary use of medical records was held. This presentation illustrated: 1) the mechanism of opt-in consent; 2) how selection bias can arise; 3) the mechanism of opt-out consent; 4) the advantages and disadvantages of opt-out consent, as compared to opt-in. Participants were asked to illustrate their reactions to an opt-out consent methodology, discussing the favourable aspects of such and their concerns. The discussion was framed on a set of questions developed on the common themes identified in the literature review (Table 1), however participants were encouraged to voice any other relevant ideas and free discussion amongst the group was supported.

Further validation for the focus group findings was also sought from the South East London Consumer Research Panel on Cancer (SELCRP). This is a group of patients, patient advocates and researcher representatives providing advice to researchers on study proposals and other topical issues. The SELCRP received the same brief presentation on selection bias and opt-out research as the focus group. Subsequently, representatives were encouraged to voice their views on presupposed consent for medical research.

Data analysis

107 The focus group was fully audio recorded and transcribed verbatim. The resulting
108 transcript was analysed thematically, coding topics mentioned with the NVivo 11 software (QRS
109 international, 2017).(21) Emergent themes were identified and grouped into broader statements,
110 which were furtherly elucidated in view of the literature review findings.

111

112 **Institutional experience of opt-out consent**

113 Consecutive patients entering an ethically approved opt-out clinical database for patients
114 with cancer of the upper gastro-intestinal tract at our institution were observed over a one year
115 period for tolerability and withdrawal of consent (REC 17/NW/0377). Information regarding the
116 use of data, access to data and the process for opting-out was made available to all patients as
117 standard.

118

119 **Patient and Public Involvement**

120 As outlined above, patients and public were at the centre of this work. The study aimed to
121 identify how **opt-out** can be used in future **to conduct** studies based on anonymised, routinely
122 collected data. We worked with our patient support groups to identify relevant research questions
123 and themes and also involved them in our interpretation of the findings from the systematic
124 literature review. Hence, we have full PPI support for the findings and write-up of the current
125 manuscript. The published manuscript will be shared with the wider patient support network at
126 our hospital.

127

128 **RESULTS**

129 **Literature review**

130 The PRISMA flow diagram in Figure 1 shows the 367 unique hits yielded from our search.
131 Titles and abstracts were screened. Twenty-nine titles meeting the criteria were reviewed in their
132 full text by two authors. Additional relevant studies were identified hand searching bibliographies
133 and utilising the “similar articles” function in PubMed. The resulting 13 papers included 5 studies
134 focussing on opt-out consent for the institution of biobanks,(22-26) whilst 8 addressed opt-out
135 consent for the secondary use of medical records.(27-34)

136 Characteristics of included studies are collated in Table 2. Common themes identified in
137 the literature review were subdivided into statements of support versus concern on opt-out
138 consent, and are summarised in Tables 3 and 4. As this review included qualitative studies, a
139 quantitative synthesis was not performed.

140

141 **Support of an opt-out consent strategy**

142 Ten of the thirteen studies included in this review specifically reported participants
143 supporting opt-out consent, acknowledging its importance in progressing medical knowledge.(22,
144 25-32, 34) Other rationales for support included providing benefit to others, to self or family and
145 to other patients with the same disease.(22, 24)

146 Seven studies noted participants support opt-out consent specifically because of their trust
147 in researchers or in the research institution.(22-24, 28, 30-32) In such cases, participants were
148 confident the sensitive data collected from opt-out studies would be effectively protected.

149 Participants recognised the convenience of opt-out consent, both from the viewpoint of
150 study subjects and of the organising researchers. In one paper, participants preferred opt-out over
151 other forms of consent, as it eliminates the need for redundant consenting for repeated
152 studies.(25) From researchers’ perspectives, three studies recognised that opt-out systems are
153 more cost- and time- effective than other forms of consent, thus facilitating research.(25-27)

154 **Participants** stated that presupposing consent is acceptable as long as certain safeguards
155 are present. Centrally, **participants** accepted opt-out systems insofar as the choice of opting-out is
156 clear, and possible at all times.(23, 25, 27, 33) This was argued to allow free judgement, whilst
157 providing flexibility for **subjects** changing opinion throughout the study. Also, **participants**
158 requested the anonymisation of their personal data.(23, 30, 32) Two studies reported desire for
159 the provision of an independent review group functioning as a “watchdog” protecting **subjects’**
160 interests.(27, 33)

161

162 **Concerns about an opt-out consent strategy**

163 The key concerns on opt-out consent reported by the literature regard privacy and its
164 protection. **Participants** were troubled that presupposing consent could entail loss of privacy,
165 especially due to possible breaches in confidentiality.(22, 24, 26-33) Moreover, three papers
166 reported scepticism on the security measures present to protect the confidential data
167 collected.(30, 31, 33)

168 Studies recorded adversity towards third parties’ use of data from opt-out research.
169 Participants disapproved of commercial data sharing, being concerned by use of data for purposes
170 other than benefitting patients and by third parties’ privacy policies.(28, 32, 33) Participants were
171 also concerned with inappropriate use of data by parties such as banks, mortgage and insurance
172 companies.(26, 27, 31-34) Studies **reported concerns** that inappropriate use of collected data
173 could trigger discrimination of particular ethnic and religious **groups**.(30, 31, 33)

174 Finally, the literature registered apprehension on insufficient information being provided
175 to research participants. Nine papers reported concern for inadequate details given prior to
176 formulating consent, especially regarding the purpose of the research performed and on who is
177 granted access to patients’ data.(22, 26-29, 31-34) Concern for peers not reading or being able to

178 comprehend the information provided was also noted.(26, 29, 32, 33) Additionally, one study(29)
179 reported worry on possible difficulties in indicating the will to opt-out, and one disapproved the
180 passivity of the consent obtained in opt-out systems.(26)

181

182 **Focus group**

183 Thirteen patients and carers took part in our focus group. The demographics of
184 participants are summarised in Table 5. Upon questioning, all participants had some
185 understanding of medical research and its importance, most having either been approached for or
186 taken part in research at least once. Nonetheless, prior to the presentation held, only one
187 participant could explain what opt-out consent entails, reflecting that most of the public has been
188 exposed to opt-in consent exclusively, due to its widespread use as the ethical gold standard in the
189 healthcare context. Indeed, following the presentation many participants posed questions
190 regarding the mechanisms of presupposed consent applied to secondary use of their records.
191 When participants' understanding of opt-out consent was clarified, a broad support for it was
192 registered (Table 6).

193 To facilitate analysis, participants' perceptions on opt-out consent were broadly
194 categorised into statements of either support or of concern, with representative quotations
195 reported in Table 7 and 8, respectively. Recurring themes were grouped to facilitate comparison
196 with findings arising from the literature review.

197

198 **Support of an opt-out consent strategy**

199 *Rationale for supporting opt-out research*

200 The most cited reason for supporting opt-out consent was appreciation that research
201 advances medical knowledge, fostering understanding of disease (Table 7). Participants

202 mentioned they would participate in an opt-out study to benefit future patients (Table 7).
203 Improving practice for future generations, along with gratefulness to past research subjects, the
204 hospital and the NHS, made presupposed consent in research acceptable to participants, who
205 likened it to a form of public duty (Table 7).

206

207 *Trust for researchers and research institutions*

208 Upon probing, all participants agreed having great trust in the medical institution attended
209 for treatment. Crucially, participants confided in researchers, hence would likely engage if an opt-
210 out study were to be established (Table 7). Participants were certain their care standard would be
211 unaltered in spite of any decision to opt-out from a future study (Table 7).

212

213 *Safeguards- opportunity to opt-out*

214 Participants were unambiguous that their participation in opt-out research would be
215 dependent on the key condition it were clear they could opt-out, and at any moment (Table 7).

216

217 *Harassing research requests*

218 Discussing research in general, participants were fearful of being “bombarded” or harassed
219 by researchers’ recruitment requests. Participants were apprehensive researchers could insistently
220 request participation or do so at inopportune moments, as had happened to many in the past
221 (Table 7). Specific concern was voiced on receiving unsolicited phone calls and emails by
222 researchers (Table 7). Participants felt reassured when explained that an opt-out observational
223 study of their medical records would not entail getting contacted other than for initial opting-out,
224 constituting a strong basis of preference for opt-out consent.

225

226 **Concerns about an opt-out consent strategy**

227 *Data protection and privacy*

228 Participants manifested worry for the loss of privacy that an opt-out consent system could
229 entail, presupposing that data mishandling or corruption would be inevitable (Table 8). Whilst they
230 agreed this would make them question their participation, not necessarily it would discourage
231 them to opt-out.

232

233 *Sharing information with pharmaceutical companies*

234 Participants were apprehensive the data obtained from opt-out research could be shared
235 with third parties, chiefly pharmaceutical companies. Concern was raised that these have
236 questionable data handling methods and ineffective privacy policies (Table 8). However,
237 participants also acknowledged the existence of a dilemma, constituted on one part by the
238 scepticism of the public against pharmaceutical companies, and on the other by the benefits of
239 conceding data to these, including monetary compensation supporting research and the chance of
240 contributing to the development of new drugs (Table 8).

241

242 *Inappropriate use of data by other third parties*

243 Patient's scepticism on the sharing of opt-out research data with third parties extends to
244 commercial entities other than the pharmaceutical industry, particularly mortgage and insurance
245 companies. Participants recognised that if sensitive data were shared or leaked to these,
246 discrimination towards particular groups could arise (Table 8).

247

248 *Patients' comprehension of opt-out consent*

249 As previously mentioned, most participants had no prior knowledge of opt-out consent,
250 and concern was voiced that other patients might not comprehend the functioning of an opt-out
251 system at first presentation. Allusions to the public's functional illiteracy were made, and concern
252 was voiced on the understanding of at-risk groups of patients (Table 8). Participants underlined
253 the need for clear and concise information throughout (Table 8). This would increase the
254 likelihood that they read and understood the introductory statement to an opt-out study.
255 Participants also suggested the use of descriptive illustrations, informative posters, text messages,
256 and of digital media to elucidate opting-out (Table 8).

257

258 *Desire for more information*

259 Throughout the focus group, participants underlined the desire for additional information
260 on how their data would be used and what research would be performed in an opt-out study.
261 Many supported that explaining patients the usefulness of their data through anecdotes could
262 provide them with greater incentives to participate in research, bolstering presupposed consent
263 (Table 8).

264

265 **Patient-consumer panel**

266 The participants consulted as part of the patient-consumer panel reiterated and
267 reinforced the focus group findings supporting opt-out systems. Similarly to the focus group
268 held, particular emphasis was placed upon the need for detailed yet clear information given
269 to prospective participants in research presupposing consent. The use of forms of
270 communication alternative to simple text, including images, posters, and digital media, was
271 discussed in detail and supported by participants.

272

273 **Institutional experience of opt-out consent**

274 Opt-out consent for collection of data by the designated clinical care team has been
275 an integral part of data capture for patients with upper gastro-intestinal cancer in our
276 institution for one year (35, 36). Combining ethical approval and support from a major
277 patient representative body as part of the consultation process, more than 100 consecutive
278 patients have been successfully enrolled within this system without any withdrawal of
279 consent to date. Data is explicitly for use by the clinical team and transfer to third parties,
280 including pharmaceuticals, is not permitted. Patient feedback has been extremely positive
281 and many also choose to enrol in further research projects for which study-specific consent
282 is obtained.

283

284 **DISCUSSION**

285 Combining the recurring themes from our focus group with our synthesis of existing
286 literature and institutional experience reveals the public's willingness to participate in research
287 recruiting on the basis of opt-out consent. This is motivated by the will to advance medical
288 knowledge and to benefit future generations. A novel finding from the focus group discussion is
289 support of opt-out recruitment as a form of public duty. This perception of opt-out consent
290 accords with proposed theories that research should be regarded a moral imperative.(37, 38)
291 Most importantly, it denotes underlying propensity of the public to join research, fundamental to
292 the presupposed consent of opt-out systems.

293 **Whilst the advantages of opt-out consent systems were recognised in some papers**
294 **analysed, the literature and our focus group showed participants were generally unaware of such.**
295 Only one reviewed paper noted that opt-out consent can eliminate the necessity of repeated
296 consents for singular studies.(25) This is particularly relevant considering the apprehension for

297 redundant recruitment requests uncovered during our focus group. From the researchers'
298 viewpoint, only three studies reported appreciation of opt-out systems' organisational, economic
299 and time effectiveness in respect to other consent methods.(25-27). Though discussed in the
300 introductory presentation, this was not recognized in our focus group, where only one participant
301 acknowledged the advantage of limiting selection bias. This reveals that effective education of the
302 public with regards to the benefits and conveniences of opt-out consent is essential for its
303 support.

304 Albeit focus group participants were supportive of opt-out systems, they were so at the
305 specific condition that opting-out is ensured possible, and at all times. This finding is echoed in
306 four papers included in the review.(23, 25, 27, 33) The request for this safeguard to autonomy
307 denotes the fundamentality of independent choice to participants.(23, 27, 30, 32, 33)
308 Notwithstanding these requests, focus group and literature participants failed to mention existing
309 safeguards currently present in medical research, including research ethics committees, NHS and
310 hospital governance protocols.(34, 39) This suggests participants' safeguarding requests to be
311 secondary to their unawareness of pre-existent protections, additionally implying the need for
312 greater education of the public. Overall, the trust avowed to researchers and institutions in the
313 literature and our focus group outlines the basis for support of opt-out research, however
314 elucidating present safeguards should provide further reassurance to participants, bolstering
315 support of opt-out. (22-24, 28, 30-32)

316 Two main concerns on opt-out consent were uncovered, many shared between the focus
317 group participants and the audited literature: (1) data protection and (2) third parties' use of data.
318 Firstly, participants presupposed that breaches in privacy are unavoidable, manifesting scepticism
319 on the security measures currently present – though better education about the process of data
320 anonymization should also better inform potential participants.(30, 31, 33) Secondly, participants

321 found the sharing of their data with commercial companies- chiefly the pharmaceutical industry-
322 questionable, even though they could also identify benefits in terms of new drug
323 development.(28, 32, 33) This delicate equilibrium underlying acceptability of commercial data
324 sharing should be subject of future studies, elucidating the precise circumstances warranting
325 approval by the public. With respect to use of data by companies such as banks, mortgage and
326 insurance companies, it is crucial to inform participants that such sharing and use by third party
327 companies is prohibited, both by data privacy legislation (including GDPR) and by the terms on
328 which studies are authorised by ethical committees.

329 An overarching theme arising in both our focus group and the analysed literature is the
330 necessity for additional public information regarding opt-out research. This finding was also
331 confirmed by the discussion held in the patient-consumer panel consulted. Participants in our
332 group and nine previous reports voiced concerns on receiving insufficient information regarding
333 opt-out consent, tampering with their independent choice of participation.(22, 26-29, 31-34)
334 Participants requested elucidations on the nature of the research performed and on the access to
335 their data. Indeed, participants' unawareness of the benefits of presupposed consent and of the
336 safeguards existent in research suggest that current public knowledge of opt-out research is
337 inadequate. To promote the public's perception of opt-out consent, any information supplied
338 should thus be easily accessible to all patient groups. Alternative forms of communication,
339 including text messages and digital media such as videos, were also suggested by participants.
340 Moreover, the strategic potential of publicity in gaining the approval of a wider public for opt-out
341 recruitment systems should not be undervalued.

342 We made every effort to include all relevant publications available to date through various
343 sources. In addition, clearly defined inclusion criteria were specified a priori. Nonetheless, our
344 study is limited in that we only conducted one focus group comprised of oncological patients and

345 family. Due to the participants' background and recruitment by invitation, it is possible individuals
346 highly engaged and favouring research were overrepresented. Moreover, some participants were
347 previously acquainted with the research nurse conducting the group, possibly introducing
348 response bias through social desirability. We tried to overcome these limitations by validating our
349 findings consulting an experienced research consumer panel. No new views were identified
350 through these discussions and hence we are confident that we reached a point of saturation (20).
351 Our institutional experience of opt-out consent for use of data by clinical teams has also been very
352 positive, affirming the principles outlined above in real world terms. However, it needs to be
353 highlighted that all our qualitative work has focused on those affected by cancer and it is possible
354 that this may influence their attitude in terms of health and research. Future studies should be
355 done in other chronic disease settings.

356 The findings of this study should also be considered in light of the recent changes to data
357 privacy laws in Europe. Of the papers reviewed, those performed in the UK were carried out at a
358 time when the Data Protection Act 1998 was the applicable law, whilst the Canadian study falls
359 under Canadian data protection laws, recognised by the EU as having general equivalence of effect
360 to European Data Protection law and providing an adequate degree of protection. The American
361 studies are subject to a data protection legislative framework generally less stringent than the
362 former two. Nonetheless, all three systems allow- or allowed- valid consent to be given by opt-out
363 methods.

364 The legal acceptability of opt-out as valid consent for processing personal data has
365 changed substantially in Europe with the General Data Protection Regulation (GDPR) coming into
366 force in May 2018.(40) Overall, GDPR raised the standard for consent, generally deeming opt-out
367 to be no longer sufficient in showing valid consent for processing personal data. Rather, GDPR

368 requires consent to be explicit, freely given, specific, informed and unambiguous, with opt-in
369 meeting such requirements.(40)

370 Nonetheless, it should be noted that consent is not an absolute requirement for processing
371 personal data under GDPR. Indeed, this is permitted if justified by one of six lawful bases, all
372 equivalent to consent in importance.(40) Hence, if consent is chosen as the basis for processing of
373 health data in Europe, such must be on an opt-in basis. However, if the justification for processing
374 data falls under another of the six bases outlined by GDPR, processing patient data may still be
375 lawful (for instance, using data to protect valid interests of the patient).

376 Thus, it is predicted that opt-out consent is to be superseded by opt-in consent for
377 observational research in Europe. This is only applicable if there are no other lawful bases under
378 which the data is being processed. In observational studies, researchers may consider either
379 utilising one of the alternative bases- rather than relying on consent- or fully anonymising
380 information, consequently abstracting it from the ambit of GDPR altogether. Any such decision will
381 require greater scrutiny prior to acceptance as part of a research proposal.

382

383 CONCLUSIONS

384 Consistently with the literature available, participants in our focus group were positive
385 about the use of opt-out consent in observational research. Participants understood opt-out
386 consent's benefits to scientific knowledge and future generations, also appreciating its
387 advantageousness to researchers and to participants themselves. Key concerns which emerged
388 focussed on privacy and the use of data from opt-out research by third parties. There is also an
389 irrefutable need for exhaustive yet accessible education and information on opt-out consent.
390 Improving education of the public regarding opt-out consent is likely to remove the perceived
391 barriers to this consent methodology, augmenting public trust whilst curbing misbeliefs. This, in

392 turn, could decrease selection bias in research, empowering more equitable care for all patients. A

393 potential impediment, however, is represented by the coming into force of the General Data

394 Protection Regulation in Europe.

395 **ACKNOWLEDGEMENTS**

396 We thank all the focus group participants and the members of the SELCRP for graciously
397 contributing their time to our study.

398
399 The research was also supported by the National Institute for Health Research (NIHR) BRC based
400 at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are
401 those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
402 The authors are solely responsible for the decision to publish, and preparation of the manuscript.
403
404

405 **DISCLOSURES**

406 No conflicts of interest to declare.
407

408 **ETHICAL APPROVAL**

409 Local audit approval was obtained for the focus group as part of ongoing work regarding opt out
410 consent as part of standard care.

411
412

- 414 1. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world
415 evidence—what is it and what can it tell us. *N Engl J Med*. 2016;375(23):2293-7.
- 416 2. Faria R, Hernandez Alava M, Manca A, Wailoo A. NICE DSU technical support document
417 17: the use of observational data to inform estimates of treatment effectiveness for technology
418 appraisal: methods for comparative individual patient data. Sheffield: NICE Decision Support Unit.
419 2015.
- 420 3. Booth C, Tannock I. Randomised controlled trials and population-based observational
421 research: partners in the evolution of medical evidence. *British journal of cancer*. 2014;110(3):551.
- 422 4. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the
423 representativeness of randomized controlled trial samples and implications for the external validity
424 of trial results. *Trials*. 2015;16(1):495.
- 425 5. Unger JM, Barlow WE, Martin DP, Ramsey SD, LeBlanc M, Etzioni R, et al. Comparison
426 of survival outcomes among cancer patients treated in and out of clinical trials. *JNCI: Journal of the*
427 *National Cancer Institute*. 2014;106(3).
- 428 6. Kho ME, Duffett M, Willison DJ, Cook DJ, Brouwers MC. Written informed consent and
429 selection bias in observational studies using medical records: systematic review. *Bmj*.
430 2009;338:b866.
- 431 7. Al-Shahi R, Vousden C, Warlow C. Bias from requiring explicit consent from all
432 participants in observational research: prospective, population based study. *Bmj*.
433 2005;331(7522):942.
- 434 8. Macleod U, Watt GC. The impact of consent on observational research: a comparison of
435 outcomes from consenters and non consenters to an observational study. *BMC medical research*
436 *methodology*. 2008;8(1):15.
- 437 9. Junghans C, Feder G, Hemingway H, Timmis A, Jones M. Recruiting patients to medical
438 research: double blind randomised trial of “opt-in” versus “opt-out” strategies. *Bmj*.
439 2005;331(7522):940.
- 440 10. Iversen A, Liddell K, Fear N, Hotopf M, Wessely S. Epidemiology: Consent,
441 confidentiality, and the Data Protection Act. *BMJ: British Medical Journal*. 2006;332(7534):165.
- 442 11. Cassell J, Young A. Why we should not seek individual informed consent for participation
443 in health services research. *Journal of medical ethics*. 2002;28(5):313-7.
- 444 12. Hill EM, Turner EL, Donovan JL, Martin RM. “Let’s get the best quality research we can”:
445 public awareness and acceptance of consent to use existing data in health research: a systematic
446 review and qualitative study. *BMC medical research methodology*. 2013;13(1):72.
- 447 13. Saunders B. Understanding (and) consent: a response to MacKay. *Journal of medical ethics*.
448 2016;42(3):203-4.
- 449 14. Berry JG, Ryan P, Gold MS, Braunack-Mayer AJ, Duszynski KM, Group VAULDW. A
450 randomised controlled trial to compare opt-in and opt-out parental consent for childhood vaccine
451 safety surveillance using data linkage. *Journal of medical ethics*. 2012;medethics-2011-100145.
- 452 15. Berry JG, Ryan P, Braunack-Mayer AJ, Duszynski KM, Xafis V, Gold MS. A randomised
453 controlled trial to compare opt-in and opt-out parental consent for childhood vaccine safety
454 surveillance using data linkage: study protocol. *Trials*. 2011;12(1):1.
- 455 16. Noble S, Donovan J, Turner E, Metcalfe C, Lane A, Rowlands M-A, et al. Feasibility and
456 cost of obtaining informed consent for essential review of medical records in large-scale health
457 services research. *Journal of Health Services Research & Policy*. 2009;14(2):77-81.
- 458 17. Ward HJ, Cousens SN, Smith-Bathgate B, Leitch M, Everington D, Will RG, et al.
459 Academic medicine campaign: Obstacles to conducting epidemiological research in the UK general
460 population. *BMJ: British Medical Journal*. 2004;329(7460):277.
- 461 18. Singleton P, Wadsworth M. Confidentiality and consent in medical research: Consent for
462 the use of personal medical data in research. *BMJ: British Medical Journal*. 2006;333(7561):255.

- 463 19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for
464 systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine*.
465 2009;6(7):e1000097.
- 466 20. Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, et al. What is an
467 adequate sample size? Operationalising data saturation for theory-based interview studies. *Psychol*
468 *Health*. 2010;25(10):1229-45.
- 469 21. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative research in*
470 *psychology*. 2006;3(2):77-101.
- 471 22. Brothers KB, Westbrook MJ, Wright MF, Myers JA, Morrison DR, Madison JL, et al.
472 Patient awareness and approval for an opt-out genomic biorepository. *Personalized medicine*.
473 2013;10(4):349-59.
- 474 23. Brothers KB, Morrison DR, Clayton EW. Two large-scale surveys on community attitudes
475 toward an opt-out biobank. *American Journal of Medical Genetics Part A*. 2011;155(12):2982-90.
- 476 24. Brothers KB, Clayton EW. Parental perspectives on a pediatric human non-subjects
477 biobank. *AJOB primary research*. 2012;3(3):21-9.
- 478 25. Lewis C, Clotworthy M, Hilton S, Magee C, Robertson MJ, Stubbins LJ, et al. Consent for
479 the use of human biological samples for biomedical research: a mixed methods study exploring the
480 UK public's preferences. *BMJ Open*. 2013;3(8).
- 481 26. Simon CM, L'heureux J, Murray JC, Winokur P, Weiner G, Newbury E, et al. Active choice
482 but not too active: public perspectives on biobank consent models. *Genetics in Medicine*.
483 2011;13(9):821-31.
- 484 27. Botkin JR, Rothwell E, Anderson R, Stark LA, Mitchell J. Public attitudes regarding the use
485 of electronic health information and residual clinical tissues for research. *Journal of community*
486 *genetics*. 2014;5(3):205-13.
- 487 28. Damschroder LJ, Pritts JL, Neblo MA, Kalarickal RJ, Creswell JW, Hayward RA. Patients,
488 privacy and trust: Patients' willingness to allow researchers to access their medical records. *Social*
489 *science & medicine*. 2007;64(1):223-35.
- 490 29. Fernandes DM, Roland AP, Morris MC. Parental opinions regarding an opt-out consent
491 process for inpatient pediatric prospective observational research in the US. *Pragmatic and*
492 *Observational Research*. 2017;8:1.
- 493 30. Kass NE, Natowicz MR, Hull SC, Faden RR, Plantinga L, Gostin LO, et al. The use of
494 medical records in research: what do patients want? *The Journal of Law, Medicine & Ethics*.
495 2003;31(3):429-33.
- 496 31. Spencer K, Sanders C, Whitley EA, Lund D, Kaye J, Dixon WG. Patient perspectives on
497 sharing anonymized personal health data using a digital system for dynamic consent and research
498 feedback: a qualitative study. *Journal of medical Internet research*. 2016;18(4).
- 499 32. Stevenson F, Lloyd N, Harrington L, Wallace P. Use of electronic patient records for
500 research: views of patients and staff in general practice. *Family practice*. 2012;30(2):227-32.
- 501 33. Taylor MJ, Taylor N. Health research access to personal confidential data in England and
502 Wales: assessing any gap in public attitude between preferable and acceptable models of consent.
503 *Life sciences, society and policy*. 2014;10(1):15.
- 504 34. Willison DJ, Keshavjee K, Nair K, Goldsmith C, Holbrook AM. Patients' consent
505 preferences for research uses of information in electronic medical records: interview and survey
506 data. *Bmj*. 2003;326(7385):373.
- 507 35. Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, et al. Tumor stage
508 after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the
509 esophagus and esophagogastric junction. *J Clin Oncol*. 2014;32(27):2983-90.
- 510 36. Davies AR, Zylstra J, Baker CR, Gossage JA, Dellaportas D, Lagergren J, et al. A
511 comparison of the left thoracoabdominal and Ivor-Lewis esophagectomy. *Dis Esophagus*. 2017.
- 512 37. Harris J. Scientific research is a moral duty. *Journal of medical ethics*. 2005;31(4):242-8.

513 38. Schaefer GO, Emanuel EJ, Wertheimer A. The obligation to participate in biomedical
514 research. *Jama*. 2009;302(1):67-72.

515 39. Hill EM, Turner EL, Martin RM, Donovan JL. “Let’s get the best quality research we can”:
516 public awareness and acceptance of consent to use existing data in health research: a systematic
517 review and qualitative study. *BMC medical research methodology*. 2013;13(1):72.

518 40. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016
519 on the protection of natural persons with regard to the processing of personal data and on the free
520 movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)
521 (Text with EEA relevance), (2016).

524 **Figure 1.** PRISMA flow chart of literature review.

525
526

527 **Table 1.** Focus group interview questions.

Part 1	
<i>Patients' involvement and understanding of medical research</i>	What is your understanding of medical research?
	Have you or someone you know ever been approached to participate in medical research?
	Have you/would you participate in medical research?
	Do you know what an "opt-out" system is?
Part 2	
Presentation on selection bias and opt-out consent	
<i>Patients' views on opt-out consent</i>	How would you feel if an "opt-out" system were applied to medical research?
	Would you participate in an "opt-out" medical study?
	How should we inform patients about our "opt-out" system?
	Who should support & counsel patients who have questions?
	How would you feel if your anonymized data were shared with third parties?

528

529

530 **Table 2.** Summary of existing literature audited.

Author	Region	Method of data collection	Participants (number)
Botkin et al. (27)	USA	Focus groups	131
Brothers et al. (23)	USA	Telephonic survey	1022
Brothers et al. (22)	USA	In person survey	237
Brothers et al. (24)	USA	Semi-structured interviews	84
Damschroder et al. (28)	USA	Telephonic survey and deliberation session	513
Fernandes et al. (29)	USA	In person survey	166
Kass et al. (30)	USA	Single structured interview (telephonic/in person)	602
Lewis et al. (25)	UK	Focus groups and online survey	1181
Simon et al. (26)	USA	Focus groups and telephonic survey	799
Spencer et al. (31)	UK	Focus groups and interviews	40
Stevenson et al. (32)	UK	Focus groups and interviews	57
Taylor et al. (33)	UK	Focus groups and survey	28
Willison et al. (34)	Canada	Semi-structured interviews and structured, fixed response survey	123

531

532

533

Table 3. Themes supportive of opt-out consent identified in existing literature. **Blue** cells indicate themes also identified in the focus group interview held.

<i>Study</i>	<i>Rationale for supporting opt-out research</i>				<i>Trust</i>	<i>Convenience</i>		<i>Presence of safeguards</i>		
	Research advances medical knowledge	Research benefits others	Research benefits self/family	Research benefits other people with same disease	Trust researchers /research institution	Not being repeatedly asked for consent	More cost/ time effective	As long as opting-out is possible	As long as records are anonymous	As long as an independent "watchdog" exists
(27)	✓	✓					✓	✓		✓
(23)					✓			✓	✓	
(22)	✓	✓	✓	✓	✓					
(24)		✓	✓	✓	✓					
(28)	✓				✓					
(29)	✓									
(30)	✓				✓				✓	
(25)	✓					✓	✓	✓		
(26)	✓	✓					✓			
(31)	✓				✓					
(32)	✓				✓				✓	
(33)		✓						✓		✓
(34)	✓	✓								

Table 4. Themes of concern over opt-out consent identified in existing literature. **Blue** cells indicate themes also identified in the focus group interview held.

<i>Study</i>	<i>Data protection</i>		<i>Third parties and inappropriate use of data</i>			<i>Information and ability to opt-out</i>			
	Concern for privacy	Sceptical security is sufficient	Commercial use of data (drug companies)	Inappropriate use by third parties (insurances, banks)	Data basis for discrimination	Desire for more information/ explanations	Initial informative letter may not be read/understood	Difficulty in indicating will to opt-out	Passive form of consent
(27)	✓			✓		✓			
(23)									
(22)	✓					✓			
(24)	✓								
(28)	✓		✓			✓			
(29)	✓					✓	✓	✓	
(30)	✓	✓			✓				
(25)									
(26)	✓			✓		✓	✓		✓
(31)	✓	✓		✓		✓			
(32)	✓		✓	✓		✓	✓		
(33)	✓	✓	✓	✓	✓	✓	✓		
(34)				✓		✓			

Table 5. Demographics of focus group participants obtained via paper survey.

	N=13
Age (%)	
Less than 30	0 (0)
30-39	1 (10)
40-49	3 (30)
50-59	1 (10)
60-69	5 (50)
70 or over	3 (30)
Self-defined ethnicity (%)	
White British	10 (77)
White Irish	2 (15)
Ashkenazi Jewish	1 (8)
Educational level (%)	
No qualifications	3 (30)
Qualifications below degree level	6 (60)
Degree or higher	4 (40)
Relation to Guy's Hospital (%)	
Patient	10 (77)
Partner	3 (23)
Family member	0 (0)
Other carer	0 (0)
If a patient, reason for attending Guy's Hospital (%)	
Medical reason other than cancer	0 (0)
At risk of developing cancer	1 (10)
Cancer diagnosis	9 (90)
Cancer type (%)	
Bladder	1 (10)
Prostate	5 (50)
Testicular	1 (10)
Breast	2 (20)
Lung	1 (10)
Employment status (%)	
Unemployed	3 (23)
Retired	6 (46)
Full-time	4 (31)
Part-time	0 (0)
Sick-leave	0 (0)
Distance from hospital (%)	
<5 miles	5 (38)
5-10 miles	2 (15)

10-15 miles

3 (23)

15+ miles

3 (23)

Table 6. Supporting quotations from focus group participants approving opt-out consenting.

Participant identifier	Quotation
Patient #9	"I'm a big believer of the opt-out system, it makes total sense to me."
Patient #1	"I definitely believe in an opt-out system."
Patient #3	"[An opt-out system] wouldn't bother me."
Patient #5	"In the principle of an opt-out system I'm in favour of."
Partner #2	"It wouldn't be a problem!"
Patient #4	"It's fine, as long as it's crystal clear you are given the opportunity to opt out."

Table 7. Representative statements supporting an opt-out consent strategy.

<i>Rationale for supporting opt out research</i>	
Advancing medical knowledge	I think research is [useful to] understanding what happens in the body and how diseases develop, and that in turn can be used to develop treatments. That's why I'd do it.
Benefitting future generations	[I'd participate] for my children, grandchildren, any children. For the next generation, that's why I'd do it.
Gratefulness to past participants	I feel very strongly that I am standing on the shoulders of other people who developed and supported research, medicine, cures up to this point. My job is to continue this.
<i>Trust for researchers and research institutions</i>	
Participation and trust in researchers	We have great trust in you, we do, that's why we wouldn't drop out.
Participation and care standards	<i>Interviewer:</i> Do you think you'd have a different level of care if you didn't take part in an opt-out study? <i>Patient #5:</i> No, not at all <i>All:</i> [shaking heads]
<i>Safeguards- opportunity to opt-out</i>	
Safeguard of clear opt-out choice	As long as it's clear you are given the opportunity to opt out, it's fine. If you got the option [to opt-out] and it's clear, wouldn't bother me.
<i>Harassing research requests</i>	
Concern for harassment resolved with opt-out	You always think you're going to get harassed, you need something to make that clear, that you're not going to be inundated with calls, emails... [It should be] made clear and honest that you're not going to get contacted and anything like that, even when you're in. You want to make it clear to people that staying in doesn't mean you're going to get bombarded.

Table 8. Representative statements of concerns on an opt-out consent strategy.

<i>Data protection and privacy</i>	
Inevitability of data corruption	I realize that there is always a risk that data is leaked. [...] I think it's about trust, we live in that era... is your stuff safe? I don't suppose it's safe no matter where it is so straight away I'm on the defence.
Knowledge of safeguards to privacy	There are laws about this kind of information. [...] I'm sure that none of them are perfect, but there is still value in having some guards on it. And I guess that's one thing that matters, assuming that no system is ever perfect; have we put safeguards in there? [...] Part of it is how do we make sure that we know when [breaches] happen and how can we control that.
<i>Sharing information with pharmaceutical companies</i>	
Third parties and data	I am really happy to share information and data but I don't necessarily want drug companies to use my data, because I think they are deeply dodgy in how the deal with data.
Dilemma of sharing data with pharmaceutical companies	The problem is that pharmaceutical companies <i>do</i> genuinely do useful research, so there's a real dilemma here. You need a data set to say that this is a drug that is worthwhile for drug companies to make, that's why we need to give data to drug companies.
<i>Inappropriate use of data by other third parties</i>	
Discrimination by inappropriate data use	I think there are patient concerns around insurances, mortgages and other things, about them discriminating patients with data. I'd actually think that for lots of people who want to get a mortgage or a loan or health insurance this data would really need to be protected.
<i>Patients' comprehension of opt-out consent</i>	
Patients unable to understand opt-out paperwork	It must be very simple because people won't read it if it's a lot of text. It's going to be quite difficult to get the right balance between information and access, as they say the reading age of the UK is a 9-year-old, so a lot of patients won't be able to even understand complex texts. Especially for elderly patients, or patients who haven't been in the UK that long, come from a different culture: there are all sorts of reasons because people might not get it.
Clarity of information given	It's about making people understand: educating, understanding and being clear and concise about it.
Use of digital media for information	Does everyone here get a text message before their appointment? There could be a link on the bottom of that, so when you press that link on your phone it goes straight to a video.
<i>Desire for more information</i>	

Informing
patients
provides
incentive to
participation

There's also a story to be told like: "These are the diseases we figured how to treat through data". [...] It's a story to be told, it's not just someone in a lab experimenting and sometimes getting it right... [...]

There's a story about it which is more than information, it's about sense-making for people: "This is why data matters, this is why you should be thoughtful about your data, and this is also why you might want to consider not opting-out."

It's quite important: how do you keep people giving their data? Making them feel proud about what they've done.